The development of genetic engineering has enabled the modification of stem cells and somatic cells.T cells exert immune responses against cancer cells.Efforts to redirect T cell specificity of a chimeric antigen rece...The development of genetic engineering has enabled the modification of stem cells and somatic cells.T cells exert immune responses against cancer cells.Efforts to redirect T cell specificity of a chimeric antigen receptor(CAR)to a desired antigen began in the 1990s(Gross et al.,1989;Kuwana et al.,1987).In 2006,the first clinical trial using carbonic anhydrase IX CAR-T cells to fight renal cancer was conducted(Lamers et al.,2006).Until 2011,Porter et al.exploited CD19 CAR-T to treat refractory/relapsed chronic lymphoid leukemia(Porter et al.,2011).Subsequently。展开更多
文摘The development of genetic engineering has enabled the modification of stem cells and somatic cells.T cells exert immune responses against cancer cells.Efforts to redirect T cell specificity of a chimeric antigen receptor(CAR)to a desired antigen began in the 1990s(Gross et al.,1989;Kuwana et al.,1987).In 2006,the first clinical trial using carbonic anhydrase IX CAR-T cells to fight renal cancer was conducted(Lamers et al.,2006).Until 2011,Porter et al.exploited CD19 CAR-T to treat refractory/relapsed chronic lymphoid leukemia(Porter et al.,2011).Subsequently。
